PRIMARY OPEN-ANGLE GLAUCOMA IN ONCOLOGIC PATIENTS

Cover Page


Cite item

Abstract

Background: Glaucoma-induced visual impairment negatively influences quality of life of oncologic patients. Yet, tumor in itself and methods of its treatment may promote glaucoma progression. 

Aim: To study characteristics and course of primary open-angle glaucoma in oncologic patients. 

Materials and methods: We analyzed case reports of 19 oncologic patients after primary open-angle glaucoma-related sinus trabeculectomy (34 eyes) and laser cyclopexy (1 eye). Diagnosed malignancies included colorectal cancer in 5 patients, uterine body and cervical cancer in 4 patients, chronic lymphocytic leukemia in 1 patient, renal cell carcinoma in 1 patient, adrenal cancer in 1 patient, prostatic cancer in 1 patient, breast cancer in 1 patient, vulvar cancer in 1 patient, tongue root cancer in 1 patient. Antiglaucomatous surgery was accomplished during the first 5 years from the diagnosis of tumor in 14 patients. In 9 patients, chemotherapy or hormone therapy was continued by the time of surgery. Follow-up of the patients was undertaken in 4–12 months after the antiglaucomatous operation; it included routine ophthalmological examination and dry eye syndrome functional tests. 

Results: Duration of postoperative period was 4 months or more. All patients had uveitis postoperatively. During late postoperative period, choroidal detachment was diagnosed in 4 patients. Bleb scarring was found in 2 patients. All patients received hypotensive treatment postoperatively including selective and non-selective beta-adrenergic blockers. Conjunctival and corneal xerosis was observed in all patients. 

Conclusion: In oncologic patients undergoing antiglaucomatous surgery, long-term (4 months or more) postoperative anti-inflammatory therapy is needed along with monthly ophthalmological follow-up during the first year after the operation. In patients with ongoing cytostatic drug treatment, artificial tear should be administrated.

About the authors

A. A. Ryabtseva

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD,Professor, the Head of the Ophthalmology Department

Russian Federation

E. E. Grishina

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: eyelena@mail.ru

MD, PhD, Professor, Leading Research Associate, Ophthalmology Department

Russian Federation

References

  1. Нестеров АП. Глаукома – дискуссионные проблемы. Клиническая офтальмология. 2004;(2):49–51. (Nesterov AP. [Glaucoma: disputable issues]. Klinicheskaya oftal’mologiya. 2004;(2):49–51. Russian).
  2. Мошетова ЛК, Алексеев ИБ, Нестеренко ЕВ. Особенности лечебной тактики при хирургическом лечении глаукомы у больных сахарным диабетом II типа (обзор литературы). Глаукома. 2005;(1):63–9. (Moshetova LK, Alekseev IB, Nesterenko EV. [Special aspects of glaucoma surgery in patients with type II diabetes mellitus (a review)].Glaukoma. 2005;(1):63–9. Russian).
  3. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113(7):1069–76.
  4. Гришина ЕЕ, Агеенкова ОА. Воспалительные заболевания глаз у больных гемобластозами. Клиническая офтальмология. 2006;(1):10–1. (Grishina EE, Ageenkova OA. [Infammatory eye diseases in patients with hemoblastosis]. Klinicheskaya oftal’mologiya. 2006;(1):10–1. Russian).

Copyright (c) 2015 Ryabtseva A.A., Grishina E.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies